Objective and subjective measures of dalfampridine efficacy in clinical practice

Multiple Sclerosis Journal – Experimental, Translational and Clinical

SylviaKlineova¹ 

关键词: Multiple sclerosis;    gait;    dalfampridine;    treatment response;    timed 25 foot walk;    outcome measurement;   

DOI  :  10.1177/2055217318786742

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

BackgroundMultiple sclerosis affects mobility in over 80% of patients. Dalfampridine is the only approved treatment for walking impairment in multiple sclerosis. We assessed dalfampridine utilization in our practice and investigated response using timed 25 foot walk (T25FW) improvement and a patient-reported ambulation inventory.MethodsChart review identified patients with multiple sclerosis for whom dalfampridine was prescribed. T25FW data were extracted from medical records. Participants completed a dalfampridine-specific version of the multiple sclerosis walking scale (dMSWS-12) to assess the qualitative impact of dalfampridine on ambulation. We evaluated two responder categories: liberally defined as any improvement in T25FW; and over 20% T25FW improvement.ResultsThe dMSWS-12 questionnaire was completed by 39 patients. Eighteen patients (46%) did not show any T25FW improvement. Of the 21 patients (54%) with T25FW improvement, four patients (11%) showed improvement greater than 20%. Analysis of dMSWS-1...

【 授权许可】

CC BY-NC